This podcast episode focuses on women's sexual health during menopause, the misinterpretations surrounding hormone replacement therapy (HRT) stemming from the Women's Health Initiative (WHI) study, and the current inadequate medical training in HRT. The speakers discuss the roles of estrogen, progesterone, and testosterone in women's health, address common misconceptions about HRT, and provide guidance on navigating menopause care.
Misinterpretation of the WHI Study: The WHI study's results were misinterpreted, leading to widespread fear and underutilization of HRT, despite evidence showing benefits in reducing risks of colon cancer, fractures, diabetes, and overall mortality in some cases.
Importance of Testosterone in Women: Testosterone plays a crucial role in women's sexual health and experiences an age-related decline, impacting libido, genital health, and urinary tract function. It is often overlooked in standard women's health care.
HRT Playbook: The speakers outline an HRT approach, emphasizing individualized treatment based on symptoms and responses to different hormone types and delivery methods (oral, topical, vaginal). They highlight micronized progesterone and various estradiol options, noting the need for progesterone when a uterus is present to protect the endometrial lining. The importance of local estrogen therapy (vaginal) for urinary and vaginal health is also underscored.
Navigating Menopause Care: The conversation stresses the importance of finding knowledgeable healthcare providers, advocating for oneself, and understanding the available options for hormone therapy. They caution against unregulated hormone clinics and the misuse of compounded formulations.
Lab Testing: The speakers strongly advocate for using LC-MS assays for accurate hormone level testing, emphasizing the unreliability of ELISA-based assays due to interference from other substances.
Despite the overall negative interpretation, the WHI study showed that using estrogen and progesterone, or estrogen alone, resulted in a decreased risk of colon cancer, fractures (a significant decrease), and diabetes. Additionally, there was a decrease in overall mortality and cancer-specific mortality.
The age-related decline in testosterone in women impacts not only libido but also genital and urinary tract health, increasing the risk of UTIs and pain during intercourse. Some studies suggest a potential link to increased depression and anxiety due to testosterone's effects on the brain.
Systemic estradiol can be administered through patches, gels, rings (inserted vaginally), oral tablets, and injections. Patches and gels offer transdermal delivery, avoiding first-pass metabolism through the liver, potentially leading to better sexual function and fewer blood clot risks compared to oral estradiol. Oral estradiol is convenient but may increase blood clot risk, particularly in women with risk factors. Injections offer another systemic option.
Key indicators of subpar or potentially harmful menopause care include a provider offering only one type of hormone therapy, dismissing a patient's concerns, recommending only expensive compounded products, performing unnecessary or excessive lab testing (like frequent saliva tests), and possessing an in-house compounding pharmacy potentially generating extra profit for the clinic.
Beyond the main focus on HRT and menopause, the podcast also covered:
Rachel Rubin's background and training: Her path from urology to specializing in women's sexual health and menopause care was discussed, highlighting the importance of quality-of-life considerations in urology and the underrepresentation of women's genital health in medical training.
Physiological changes during ovulation and perimenopause: A detailed explanation of hormonal fluctuations throughout the menstrual cycle, including the roles of FSH, LH, estrogen, and progesterone, and how these become erratic during perimenopause.
The impact of progesterone withdrawal: The discussion addressed why women experience varying degrees of sensitivity to the sharp drop in progesterone during the luteal phase and after menopause, linking it to individual receptor sensitivity.
The underappreciated role of testosterone in women's health: The podcast emphasized the significance of testosterone in various aspects of women's well-being beyond sexual function and its age-related decline.
The consequences of the medical system's failure to train doctors adequately in HRT: This section explored the lasting impact of the WHI study's misinterpretation on menopause care, leading to a lack of knowledge among physicians and the rise of unregulated hormone clinics.
The use of DHEA and testosterone in treating hormone-sensitive genital tissues: The discussion included how these hormones, particularly in vaginal delivery methods, can improve symptoms like UTIs, vaginal dryness, and sexual function.
The timing of HRT initiation and duration: The speakers addressed whether it's "too late" to start HRT after menopause and whether it needs to be stopped after a certain period, arguing against arbitrary time limits based on current evidence.
Managing HRT in women with BRCA mutations or a history of breast cancer: The discussion included how to approach HRT in these high-risk patients, balancing the benefits against potential risks and prioritizing shared decision-making.
Identifying good menopause care providers: Advice was given on how to identify qualified providers and navigate potentially exploitative practices.
The wide-ranging symptoms of menopause: The podcast went beyond typical hot flashes to encompass joint pain, brain fog, and mood issues, linking these to hormonal imbalances.
The evolution of medical terminology related to menopause: The historical evolution of terms used to describe vaginal changes in menopause, from "senile vagina" to "genitourinary syndrome of menopause" (GSM), was highlighted to showcase a shift toward more accurate and less stigmatizing language.
The importance of local estrogen therapy for urinary and vaginal health: The podcast strongly advocated for local estrogen therapy for the treatment of GSM, emphasizing its safety and effectiveness in treating urinary and vaginal symptoms.
